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ABSTRACT
Background
Malaria vaccines based on the 19-kDa region of merozoite surface protein 1 (MSP-119)
derived from the 3D7 strain of Plasmodium falciparum are being tested in clinical trials in Africa.
Knowledge of the distribution and natural dynamics of vaccine antigen polymorphisms in
populations in which malaria vaccines will be tested will guide vaccine design and permit
distinction between natural fluctuations in genetic diversity and vaccine-induced selection.
Methods and Findings
Using pyrosequencing, six single-nucleotide polymorphisms in the nucleotide sequence
encoding MSP-119 were genotyped from 1,363 malaria infections experienced by 100 children
who participated in a prospective cohort study in Mali from 1999 to 2001. The frequencies of 14
MSP-119 haplotypes were compared over the course of the malaria transmission season for all
three years, in three age groups, and in consecutive infections within individuals. While the
frequency of individual MSP-119 haplotypes fluctuated, haplotypes corresponding to FVO and
FUP strains of P. falciparum (MSP-119 haplotypes QKSNGL and EKSNGL, respectively) were most
prevalent during three consecutive years and in all age groups with overall prevalences of 46%
(95% confidence interval [CI] 44%–49%) and 36% (95% CI 34%–39%), respectively. The 3D7
haplotype had a lower overall prevalence of 16% (95% CI 14%–18%). Multiplicity of infection
based on MSP-119 was higher at the beginning of the transmission season and in the oldest
individuals (aged  11 y). Three MSP-119 haplotypes had a reduced frequency in symptomatic
infections compared to asymptomatic infections. Analyses of the dynamics of MSP-119
polymorphisms in consecutive infections implicate three polymorphisms (at positions 1691,
1700, and 1701) as being particularly important in determining allele specificity of anti-MSP-119
immunity.
Conclusions
Parasites with MSP-119 haplotypes different from that of the leading vaccine strain were
consistently the most prevalent at a vaccine trial site. If immunity elicited by an MSP-1-based
vaccine is allele-specific, a vaccine based on either the FVO or FUP strain might have better
initial efficacy at this site. This study, to our knowledge the largest of its kind to date, provides
molecular information needed to interpret population responses to MSP-1-based vaccines and
suggests that certain MSP-119 polymorphisms may be relevant to cross-protective immunity.
The Editors’ Summary of this article follows the references.
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Malaria remains a major cause of disease and death
worldwide, killing millions every year [1]. The most severe
form of the disease is caused by Plasmodium falciparum, which is
responsible for most malaria mortality. Reducing the malaria
burden will require the coordinated use of several strategies,
including combination antimalarial therapies, insecticide-
treated nets and, potentially, malaria vaccines [2].
Progress toward a malaria vaccine has been slow, owing in
part to extensive genetic diversity in candidate vaccine
antigens. As with other genetically diverse pathogens such
as inﬂuenza virus, Streptococcus pneumoniae, and HIV, vaccines
based on polymorphic malaria proteins may not elicit
responses against all variants of the target antigen circulating
in the parasite population. Immunization with such a malaria
vaccine could lead to an increased frequency of variants not
targeted by the vaccine. This phenomenon has been observed
in trials of pneumococcal vaccines in which carriage of
nonvaccine serotypes increased in vaccinated individuals
[3,4], and continues to be a concern as nonvaccine serotypes
have expanded following licensure of the seven-valent
conjugate vaccine, PCV7 [5,6]. Inﬂuenza surveillance data
are reviewed twice a year to determine which virus strains
should be included in the vaccines for the upcoming
transmission season [7]. A similar strategy has been proposed
for development of HIV vaccines, whereby vaccine targets
would be based on the genetic makeup of the viruses
circulating in the target population [8]. However, the
extensive genetic diversity and rapid evolution of these
viruses could lead to the generation of vaccine-resistant
strains. Malaria vaccine developers may face similar chal-
lenges.
Several subunit malaria vaccines in clinical development
are based on merozoite surface protein 1 (MSP-1), the major
protein on the surface of the extracellular blood stage of the
parasite. The protein is synthesized as a 190 kDa precursor,
which undergoes proteolytic cleavage into four fragments
that remain on the surface of the merozoite as a glycosyl-
phosphatidylinositol-anchored complex. Prior to erythrocyte
invasion, the entire MSP-1 complex is shed, except for the C-
terminal 19 kDa (MSP-119), which remains on the merozoite’s
surface as it enters the erythrocyte [9]. MSP-119 contains two
epidermal growth factor (EGF)-like domains, which are
thought to play a role in erythrocyte invasion [10]. Naturally
acquired antibodies to MSP-119 can inhibit erythrocyte
invasion by preventing the secondary processing that releases
this fragment from the rest of the MSP-1 complex [9,11,12],
and are associated with protection from clinical malaria in
ﬁeld studies [13–18].
MSP-119 has a highly conserved sequence, which along with
its hypothesized critical function, makes it an attractive
vaccine target. However, this region contains six nonsynon-
ymous single nucleotide polymorphisms (SNPs): one in the
ﬁrst EGF-like domain corresponding to amino acid position
1644 (Q/E) and ﬁve in the second EGF-like domain
corresponding to positions 1691 (K/T), 1699 (S/N), 1700 (N/
S), 1701 (G/R), and 1716 (L/F) [19–23]. It is not clear what
impact these polymorphisms have on anti-MSP-119 immunity.
Studies have demonstrated cross-reactive antibody responses
between MSP-119 haplotypes [24,25], but also some differ-
ential recognition [24–27], particularly of amino acids in the
second EGF-like domain [24,25].
The FMP1/AS02A malaria vaccine, which is currently being
tested in the ﬁeld [28–30], is based on the C-terminal 42 kDa
of MSP-1 from the 3D7 strain of P. falciparum [31] and
contains amino acids ETSSRL at the six polymorphic residues
in MSP-119. Other P. falciparum strains are being targeted for
MSP-1-based vaccines as well, including FVO and FUP, which
have MSP-119 haplotypes QKSNGL and EKSNGL, respec-
tively. If immunity conferred by a vaccine is allele speciﬁc,
then vaccination could increase the frequency of alleles not
targeted by the vaccine and compromise vaccine efﬁcacy. In a
recent Phase I trial in Mali, West Africa, sera from adults
immunized with a malaria vaccine based on the 3D7 strain
reacted to FVO and FUP as well as to 3D7 parasites [30]. Only
a few malaria vaccine candidates have been tested in efﬁcacy
trials powered to detect vaccine-induced selective effects [32–
35]. The results of a Phase II trial of a blood stage vaccine
suggested possible selection for clinical infections with
nonvaccine type parasites in vaccinated individuals [34].
In preparation for efﬁcacy trials of vaccines against malaria
and other genetically variable pathogens, it is important to
understand the distribution and natural dynamics of vaccine
antigen polymorphisms in endemic populations. Molecular
epidemiological studies will guide vaccine design and provide
information that is needed to measure and interpret
population responses to vaccines, both during efﬁcacy trials
and after introduction of vaccines into the population, and
may provide insight into the selective forces (e.g., immunity)
acting on antigen genes. In the largest study, to our
knowledge, of malaria genetic diversity to date, we have
determined the prevalence and dynamics of MSP-119 hap-
lotypes, both at a population level and within individuals, in a
cohort of children and young adults residing at a malaria
vaccine-testing site in Mali who were followed for three years
during a malaria incidence study.
Methods
Study Site
Bandiagara is a rural town with 13,634 inhabitants in the
Dogon Country of northeastern Mali. Mean annual rainfall is
approximately 600 mm, and Anopheles gambiae is the primary
vector for malaria. P. falciparum has intense, seasonal trans-
mission corresponding to the July–October rainy season, with
peak monthly entomological inoculation rates (EIRs) of up to
40–60 infected bites per person per month in September and
total annual EIRs of 50–150. EIRs at the start and end of the
transmission season (in June and December, respectively) are
less than 1 infectious bite per person per month [36]. P.
falciparum accounts for 97% of malaria infections, P. malariae
for 3%, and P. ovale for rare infections. The disease burden is
high, with children aged 10 y or less experiencing a mean of
two clinical episodes of uncomplicated malaria a year [36]
and a 2.3% annual incidence of severe malaria among
children aged 6 y or less [37].
Study Design
The samples used in this study were collected during a
cohort study designed to measure the age-speciﬁc incidence
of malaria infection and disease in children and young adults
in Bandiagara. The study was conducted prospectively during
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3 mo to 20 y and were recruited from all eight sectors of
Bandiagara town in proportion to the populations of those
sectors. From July to January of each year, individuals were
followed actively by weekly visits. Each visit included a brief
clinical examination, and those with symptoms consistent
with malaria were given a full medical and laboratory
assessment. Each participant contributed approximately 0.1
ml of blood, collected on 3MM Whatman ﬁlter paper
(Whatman, http://www.whatman.com), at least monthly and
at every episode of clinical malaria. Samples were collected
under protocols reviewed and approved by Institutional
Review Boards of the University of Maryland School of
Medicine and the University of Bamako Faculty of Medicine.
Informed consent was obtained from all study participants or
their guardians.
For this study, 100 individuals with at least two years of
follow-up during the malaria incidence study were randomly
selected within three age strata. Thirty children aged 5 y or
younger, 32 aged 6–10 y, and 38 aged 11 y or older were
selected. Individuals selected for analysis did not differ from
those not selected with respect to age, gender, or incidence of
clinical malaria (unpublished data). Blood samples (n¼2,309)
corresponding to all monthly surveys (n ¼ 1,801) and clinical
episodes (n ¼ 508) occurring during the transmission season
of the three years of the incidence study underwent DNA
extraction (QIAamp DNA Mini Kit, Qiagen, http://www.
qiagen.com) and PCR, and those yielding PCR products
underwent pyrosequencing and haplotype estimation.
PCR
As described previously [38], PCR to amplify the nucleotide
sequence encoding MSP-119 was performed on samples
collected at all monthly surveys (regardless of microscopy
results) and clinical episodes. A single PCR was used to
amplify the region of interest from samples with parasitemia
over 1,000 parasites/ll using biotinylated PCR primers
(forward, 59-CAATGCGTAAAAAAACAATGTCC-39; reverse,
59BIOTIN-TTAGAGGAACTGCAGAAAATACCA-39). For
samples with parasitemia below 1,000 parasites/ll and micro-
scopy-negative samples, a nested PCR was used to amplify this
region, using the above primers for the internal reaction and
the following PCR primers for the external reaction: forward,
59-TTAAACATTTCACAACACCAATG-39; reverse, 59-GAG-
TATTAATAAGAATGATATTCCTAAG-39. Experiments com-
paring allele frequencies determined via single versus nested
PCR showed no signiﬁcant difference in allele frequencies (n
¼ 64, mean difference in allele frequencies  0.5%,  0.2%,
1.6%,  0.7%, 0.4%, and  0.3% for the six SNPs of interest).
The same reagent concentrations were used for both the
single and nested PCR reactions and are described in a
previous study [38], as are the cycling conditions for the single
PCR. Cycling conditions for the external PCR included ten
touchdown cycles beginning at a 63 8C annealing temperature
with incremental changes of  0.5 8C/cycle, followed by 35
cycles with a 58 8C annealing temperature. The internal PCR
used 2 ll of external PCR as template and ran for 25 cycles at
a6 08C annealing temperature. The 272 bp PCR products
were visualized on 1.5% agarose gels. Samples that did not
yield a product using the nested PCR were considered
parasite-negative.
Pyrosequencing
Using previously published methods, all PCR-positive
samples underwent pyrosequencing to determine allele
frequencies at each of the six SNPs in the nucleotide
sequence encoding MSP-119 [38]. Pyrosequencing (Biotage,
http://www.pyrosequencing.com) is a high-throughput, real-
time sequencing method that allows sequencing of short
stretches of nucleotides (10–20 bp) surrounding known
polymorphisms and quantiﬁcation of the proportions of
alternative nucleotides at each SNP. Four pyrosequencing
reactions were used to genotype the six SNPs of interest.
Haplotype Estimation
A mathematical model was used to estimate the frequency
of 14 haplotypes in each genotyped sample given the allele
frequencies generated by pyrosequencing [38]. The haplo-
type-estimating algorithm uses maximum likelihood methods
to determine the most probable combination of haplotypes
given the allele frequencies for an infection, the haplotypes
known to be circulating in the population, and a probability
distribution of the measurement errors.
Statistical Analysis
Each parasite-positive sample (infection) was classiﬁed as
having or not having each of the haplotypes. A haplotype was
classiﬁedasbeing‘‘present’’ifitsfrequencyintheinfectionwas
above 10%. Infections could have more than one haplotype,
and therefore, the sum of the prevalences of all the haplotypes
was greater than one. Multiplicity of infection (MOI) was a
count of the number of haplotypes in a given infection.
To investigate population-level dynamics, the prevalence of
each MSP-119 haplotype was compared over the course of the
transmission season within each year, between the three
years, and between the three age groups using chi-squared
tests. Multivariable regression analysis was performed using
generalized estimating equations (GEE) to model the log odds
of each outcome of interest (MSP-119 haplotype, MOI .1, and
symptoms) as a function of time, age, and other covariates,
and taking into account repeated measurements from the
same individual.
To investigate within-host dynamics, each infection was
classiﬁed as predominant or mixed with respect to the 14
haplotypes and with respect to each of the six polymorphic
residues. A haplotype or individual amino acid was consid-
ered ‘‘predominant’’ in the infection if its frequency was over
60%, and infections without a predominant haplotype/amino
acid were considered ‘‘mixed.’’
Cox proportional hazards was used to model the time to
next clinical episode in individuals’ consecutive clinical
infections as a function of change in predominant haplotype
(or predominant amino acid at each polymorphic site), year,
and age. The ﬁxed effects partial likelihood method was used
to determine the effect of having multiple events from the
same individual.
Logistic regression was used to model the log odds of a
change in predominant haplotype/amino acid in intervals
consisting of an asymptomatic infection followed by a clinical
episode versus intervals containing consecutive asympto-
matic infections, adjusting for year, age, and interval length.
GEE was also used in the same models to account for multiple
intervals occurring in the same individual. No corrections
were made for testing of multiple sites. For all analyses, only
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included; intervals spanning a dry season were not included.
Statistical analysis was conducted using SAS (SAS Institute,
http://www.sas.com).
Results
Prevalence and Population Dynamics of 14 MSP-119
Haplotypes
Of the 2,309 samples collected from the study participants
during the three transmission seasons, 1,375 were parasite-
positive (by PCR). Of the samples positive for parasites by
microscopy, 96% were PCR positive, and of microscopy-
negative samples, 40% were PCR positive. Of the 1,375
parasite-positive samples, 1,369 gave successful genotyping
results. A haplotype-estimating algorithm was used to
determine the presence of 14 haplotypes in samples that
yielded allele frequency data. The algorithm was able to
resolve haplotype frequencies for 1,363 of the 1,369 geno-
typed samples. The overall prevalence of each haplotype in
the 1,363 samples is shown in Figure 1. The QKSNGL and
EKSNGL haplotypes (corresponding to the FVO and FUP
strains, respectively) had the highest prevalence in the cohort
with prevalences of 46% (95% conﬁdence interval [CI] 44%–
49%) and 36% (95% CI 34%–39%), respectively. The
ETSSRL haplotype (corresponding to the 3D7 strain) had a
lower overall prevalence of 16% (95% CI 14%–18%). Ten of
the 14 haplotypes had prevalences below 10%, and eight
haplotypes had prevalences below 5%.
Figure 2 shows the prevalence of MSP-119 haplotypes over
time in three age groups. As seen in the ﬁgure, the frequency
of individual haplotypes varied considerably over time.
However, despite this variability, the QKSNGL (FVO) and
EKSNGL (FUP) haplotypes were most prevalent during all
three years and in all three age groups. In addition, it
appeared that the difference in prevalence between the two
most common types and the remaining types increased with
age. The same patterns were observed when the analysis was
limited to microscopy-positive samples (unpublished data).
Multiplicity of Infection
Figure 3 shows the average MOI in three age groups during
the three years of the incidence study. Average MOI
ﬂuctuated over time, but overall tended to decrease over
the course of the transmission season (Mantel-Haenszel Chi-
square test for trend p ¼0.074, p , 0.001, p¼0.027, for 1999,
2000, and 2001, respectively, for all age groups combined). In
addition, MOI was higher in the oldest age group ( 11 y) than
in the two younger age groups. In a multivariable regression
model including month, study year, age, and parasite density
and taking into account repeated measurements from the
same individual, persons 11 years of age or older had a 2.7
times greater odds of having a mixed infection (deﬁned as
having more than one MSP-119 haplotype) compared to
children 5 years of age or younger (odds ratio [OR] 2.71, 95%
CI 1.76–4.15, p , 0.001). The odds of having a mixed infection
was not signiﬁcantly different between the two younger age
groups (OR 1.22, 95% CI 0.84–1.78, p ¼ 0.24). The odds of a
mixed infection was also greater in infections with moderate
parasitemia (500–5,000 parasites/ll) compared to low-para-
sitemia infections (,500 parasites/ll) (OR 1.66, 95% CI 1.20–
2.31, p ¼ 0.0022). The odds of a mixed infection was not
signiﬁcantly different between higher-parasitemia infections
and low-parasitemia infections (OR 1.11, 95% CI 0.80–1.55, p
¼ 0.53 for 5,000–25,000 parasites/ll, and OR 1.07, 95% CI
0.75–1.53, p ¼ 0.70 for .25,000 parasites/ll).
MSP-119 Haplotype Frequencies in Symptomatic and
Asymptomatic Infections
Figure 4 shows the frequency of symptomatic and
asymptomatic infections in the cohort for all three study
years combined. As seen in Figure 4A, the incidence of
symptomatic infections peaked in October and decreased to
almost zero by January, and was lower in individuals aged 11
years or older. Asymptomatic infection was less common in
individuals aged 5 years or younger, and even in the absence
of clinical malaria, asymptomatic parasitemia persisted, with
a prevalence as high as 60% in the oldest individuals (Figure
4B).
Figure 1. Prevalences of 14 MSP-119 Haplotypes in a Cohort from Bandiagara, Mali
Infections could have multiple haplotypes, thus haplotype prevalences do not sum to one. Haplotypes corresponding to the FVO, FUP, and 3D7 strains
are indicated. Bars indicate 95% CIs.
doi:10.1371/journal.pmed.0040093.g001
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between symptomatic and asymptomatic infections, three
haplotypes (ETSSRL [3D7], QKNNGL, and EKSNGF) had a
signiﬁcantly lower prevalence among symptomatic infections
compared to asymptomatic infections (Figure 5). The same
results were observed in a multivariable model adjusting for
time and age, while taking into account longitudinal
measurements. With QKNSGL (FVO) as the reference group,
the ETSSRL (3D7), QKNNGL, and EKSNGF haplotypes had
decreased odds of being present in a symptomatic infection
(ETSSRL [3D7]: OR 0.67, 95% CI 0.49–0.92, p ¼ 0.012;
QKNNGL: OR 0.48, 95% CI 0.35–0.68, p , 0.001; and
EKSNGF: OR 0.29, 95% CI 0.09–1.02, p ¼ 0.053). When
parasite density was added to the model, these associations
were no longer signiﬁcant, suggesting that the associations
between these three haplotypes and asymptomatic infection
may be accounted for by differences in parasitemia. To test
this hypothesis, GEE was used to model the association
between each of the three haplotypes and parasite density,
adjusting for time, age, and MOI. Indeed, both ETSSRL (3D7)
and QKNNGL were more prevalent in the lowest-parasitemia
infections (,500 parasites/ll) compared to the highest-para-
sitemia infections (.25,000 parasites/ll) (ETSSRL [3D7]: OR
2.12, 95% CI 1.41–3.20, p , 0.001; QKNNGL: OR 3.65, 95% CI
2.32–5.72, p , 0.001). QKNNGL was also more prevalent in
moderate-parasitemia infections (500–5,000 parasites/ll) than
in the highest-parasitemia infections (OR 2.44, 95% CI 1.38–
4.31, p ¼ 0.0021). There were no statistically signiﬁcant
associations between the EKSNGF haplotype and parasite
density, although as one of the more rare haplotypes, the data
may have been too few for meaningful multivariable analysis.
The raw data indicate a frequency of 2.8% in the lowest
Figure 2. Prevalence of MSP-119 Haplotypes over Time in Three Age Groups
Haplotype prevalences from July to January by age group during the three years of the malaria incidence study in Bandiagara, Mali.
doi:10.1371/journal.pmed.0040093.g002
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the highest frequency infections.
Within-Host Dynamics of MSP-119 Polymorphisms
On average, individuals aged 5 years or less were parasite
positive at 14 time points during the 3-y study period, seven
of which corresponded to clinical episodes. Individuals aged
6–10 y were positive at 16 time points (six clinical episodes),
and individuals 11 y and older were positive at 12 time points
(three clinical episodes). Figure 6 shows cumulative hazard
functions generated from Cox proportional hazards models
of the time to next clinical episode in individuals’ consecutive
clinical infections as a function of change in predominant
amino acid at each of the six polymorphic residues in MSP-
119, year, and age group. The hazard of a subsequent clinical
infection when there was a change in overall haplotype was
not signiﬁcantly different from the hazard of a subsequent
clinical infection when there was not a change in haplotype
(hazard ratio [HR] 1.17, 95% CI 0.87–1.58, p¼0.30). However,
as seen in graphs for amino acid positions 1691, 1700, and
1701 in Figure 6, when a change in predominant amino acid
at each of the polymorphic residues was considered, the
hazard of a subsequent clinical episode was greater when
there was a change in predominant amino acid at these
positions than when there was no change at these positions
(1691: HR 1.48, 95% CI 1.13–1.94, p ¼ 0.0044; 1700: HR 1.48,
95%CI: 1.13–1.93, p ¼ 0.0039; 1701: HR 1.38, 95% CI 1.05–
1.80, p ¼ 0.021). The hazard of a subsequent clinical episode
when there was a change at the other three polymorphic
positions (1644, 1699, and 1701) was not signiﬁcantly differ-
ent from when there was no change (1644: HR 1.05, 95% CI
0.82–1.34, p¼0.72; 1699; HR 1.17, 95% CI 0.86–1.60, p¼0.32;
1716: HR 1.07, 95% CI 0.78–1.48, p¼0.67). These associations
were not changed when mixed infections were excluded (i.e.,
going from a predominant to mixed infection was not
considered a change) or when multiple events from the same
individual were taken into account (unpublished data). In
addition, the hazard of a subsequent clinical episode in 2000
and 2001 was less than the hazard in 1999 (2000: HR 0.53,
95% CI 0.38–0.74, p , 0.001; 2001: HR 0.56, 95% CI 0.41–1.76,
p , 0.001), and as expected, was also less for individuals aged
11 y or more compared to children aged 5 y or less (HR 0.64,
95% CI 0.45–0.92, p ¼ 0.016).
Figure 7 shows point estimates and conﬁdence intervals
comparing the odds of a change in predominant haplotype or
predominant amino at each polymorphic residue in intervals
including an asymptomatic infection followed by a sympto-
matic infection to intervals including consecutive asympto-
matic infections, adjusting for year, age, and time between
infections. The odds of a change in predominant amino acid
at residues 1691, 1700, and 1701 were signiﬁcantly greater in
intervals ending with a clinical infection compared to
intervals containing consecutive asymptomatic infections
(1691: OR 2.01, 95% CI 1.08–3.73, p ¼ 0.028; 1700: OR 1.91,
95% CI 1.04–3.48, p¼0.036; 1701: OR 1.92, 95% CI 1.04–3.52,
p¼0.036). For changes of any type, the longer the amount of
time between infections, the greater the odds of a change.
The patterns were the same when intervals including mixed
infections were excluded and when GEE was used to take into
account multiple intervals from the same individual; point
estimates were similar, but conﬁdence intervals were wider,
resulting in some associations no longer being signiﬁcant at a
¼ 0.05 (unpublished data).
Discussion
To understand the natural variation in the frequency of
polymorphisms in a malaria vaccine antigen, the nucleotide
sequence encoding MSP-119 was genotyped from 1,363 PCR-
positive samples collected from 100 individuals who partici-
pated in a malaria incidence study at this site over three
consecutive years. The two most prevalent haplotypes
corresponded to strains of P. falciparum that are not included
Figure 3. MOI by Age
Average MOI over time in three age groups.
doi:10.1371/journal.pmed.0040093.g003
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(A) Incidence of symptomatic infection over the course of the transmission season.
(B) Prevalence of parasitemia among asymptomatic monthly surveys. Values in the figure represent the average for all three years of the study, since
patterns were similar in all years. Bars indicate 95% CIs.
doi:10.1371/journal.pmed.0040093.g004
Figure 5. Prevalence of MSP-119 Haplotypes among Symptomatic and Asymptomatic Infections
Bars indicate 95% CIs. *Chi-square p-value ¼ 0.08 (ETSSRL [3D7]), p , 0.001 (QKNNGL), and p ¼ 0.006 (EKSNGF).
doi:10.1371/journal.pmed.0040093.g005
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sites in Africa, and although the frequency of individual MSP-
119 haplotypes ﬂuctuated over time, these two haplotypes
remained most prevalent during the three consecutive years
of the study and in all three age groups. MOI was higher at the
beginning of the transmission season and in older individuals.
Three MSP-119 haplotypes were associated with asympto-
matic infection, which was accounted for by their being more
prevalent in infections with low parasite density. Analyses of
the dynamics of MSP-119 polymorphisms within individuals’
consecutive infections implicate three polymorphisms as
being particularly important in determining allele speciﬁcity
of anti-MSP-119 immunity.
Implications for Malaria Vaccine Design and Testing
By providing information about the prevalence and
dynamics of vaccine antigen polymorphisms in a population
being targeted for malaria vaccines, this study will inform
choices about which MSP-119 haplotypes to include in future
vaccine formulations, and will allow more accurate interpre-
tation of the efﬁcacy of current formulations of MSP-1–based
vaccines being tested in clinical trials. For example, the FMP1
vaccine antigen is based on the C-terminal 42 kDa of MSP-1
from the 3D7 strain of P. falciparum (MSP-119 haplotype
ETSSRL) [31]. In the Malian cohort examined in this study
and in other malaria endemic areas, this haplotype is not the
most common haplotype circulating in the parasite popula-
tion [20,22,23]. The FVO (QKSNGL) and FUP (EKSNGL)
haplotypes were the most prevalent in this study and the FUP
(EKSNGL) haplotype had the highest frequency in Vietnam
[20], Kenya [22], and Thailand [23]. If immunity conferred by
such monovalent vaccines is allele speciﬁc, a vaccine with
high allele-speciﬁc efﬁcacy would have low overall efﬁcacy in
populations where the target allele is in the minority.
Without an understanding of the distribution of vaccine
target haplotypes, this scenario could result in the premature
abandonment of a promising vaccine that could be modiﬁed
(perhaps by including additional target alleles) to be more
universally protective. This possibility highlights the need to
include molecular endpoints in addition to conventional
efﬁcacy endpoints in clinical trials of malaria vaccines.
Analyses of the within-host dynamics of MSP-119 poly-
morphisms indicate that changes in amino acids at positions
1691, 1700, and 1701 are associated with a shorter time to
next clinical infection and with the development of clinical
symptoms, suggesting that these residues may be particularly
important in determining allele speciﬁcity of anti-MSP-119
immune responses. These results are consistent with previous
studies of anti-MSP-119 immunity, which suggest that there is
some differential recognition of MSP-119 haplotypes [24–27],
particularly based on polymorphic amino acids in the second
EGF-like domain [24,25]. However, sera from malaria-
experienced adults immunized with the 3D7-based FMP1/
AS02A malaria vaccine reacted to FVO and FUP as well as to
3D7 parasites [30]. Coordinated molecular epidemiological
and immunoepidemiological studies are needed to conﬁrm
the importance of these residues in determining the
dynamics of MSP-119 diversity, particularly at sites like ours
where malaria transmission is seasonal, since MSP-119 anti-
body responses wane quickly in the absence of exposure [39].
If the amino acids present at positions 1691, 1700, and 1701
do deﬁne an MSP-119 ‘‘serotype,’’ then instead of 14
haplotypes, there would be six pertinent serotypes, with the
KNG serotype (FVO and FUP) having a prevalence of 88%
and the TSR serotype (3D7) having a prevalence of 20% in
this Malian cohort. This ﬁnding greatly reduces the amount
of genetic diversity vaccine developers would need to take
into account in developing a polyvalent MSP-1–based
vaccine, allowing them to focus on the residues most relevant
to cross-protection.
Natural and Vaccine-Induced Selection
While temporal variation in the prevalence of individual
haplotypes was observed in the cohort from Mali, the relative
frequency of the haplotypes remained stable—that is, the
most prevalent haplotypes, FVO and FUP, remained most
prevalent, and rare haplotypes remained rare. Our results
contrast with the temporal changes observed in 138 isolates
from Brazil, where in 1985–1986 the FUP haplotype was
absent and the 3D7 haplotype was present in 40% of samples
collected, but in 1997–1998 the FUP haplotype was more
common than 3D7 (37% versus 10%, respectively) [19]. These
different patterns may reﬂect true differences in haplotype
dynamics in these locations, but may also have resulted from
differences in sample size, sampling interval, and study
duration.
Figure 7. Association between Change in Predominant Haplotype or
Amino Acid and Development of Clinical Symptoms
ORs comparing the odds of a change in predominant haplotype or
amino acid during intervals between two consecutive infections during
which clinical symptoms developed, to the odds of a change during
intervals between consecutive infections during which no symptoms
developed, adjusting for year, age, and time between infections.
Diamonds indicate point estimates and bars indicate 95% CIs. The
dashed line designates an OR of 1, or no effect.
doi:10.1371/journal.pmed.0040093.g007
Figure 6. Cumulative Hazard of a Subsequent Clinical Infection according to Change in Predominant Amino Acid
Cumulative hazard functions generated from Cox proportional hazards models of time to next clinical episode as a function of change in predominant
amino acid at each polymorphic residue in MSP-119, year, and age. The cumulative hazard is shown along the y-axis with days on the x-axis. Dashed
lines indicate a change in predominant amino acid and solid lines indicate no change at positions 1644, 1691, 1699, 1700, 1701, and 1716. The hazard of
a subsequent clinical episode was significantly greater when a change in predominant amino acid occurred at positions 1691, 1700 and 1701.
doi:10.1371/journal.pmed.0040093.g006
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prevalences in Mali might be due to balancing selection
acting to maintain genetic diversity at this locus, as has been
demonstrated for other regions of MSP-1 [40–42]. If vaccine-
induced immunity is allele speciﬁc, then vaccination could
disturb this equilibrium, imposing directional selection that
favors alleles not targeted by the vaccine. Such directional
selection could induce changes in haplotype frequency and
cause a reduction in vaccine efﬁcacy over time, although this
effect would likely be diluted by the substantial parasite
population maintained in unvaccinated older children and
adults. By decreasing the effective population size, vaccina-
tion could also increase the effect of genetic drift in the
parasite population, resulting in decreased stability of
haplotype frequencies. Use of insecticide-treated nets or
prolonged effective drug treatment might be expected to
have the same effect.
Genetic Diversity and Malaria Epidemiology
Although MOI based on MSP-119 is likely an underestimate
of true MOI, the observed pattern of greater MOI in older
individuals is in agreement with studies that have docu-
mented similar associations between MOI and age [43,44]. It
has been hypothesized that fevers experienced during clinical
malaria episodes may play a role in clearing parasitemia in
younger children, while older children and adults have
acquired immunity that limits disease but does not clear
genotypes below the threshold of detection [43,44]. This
hypothesis is consistent with the epidemiology of malaria in
this area of Mali, where there is a lower incidence of
symptomatic infection in individuals aged 11 years or more.
However, the increased MOI in this group could also be due
to less frequent treatment. Whatever the cause, these data
emphasize the possibility that older children and adults serve
as an important reservoir of genetic diversity.
MOI was highest at the beginning of the transmission
season and decreased over the course of the transmission
season, particularly in the two younger age groups. This
initial decrease in MOI may be due to an increase in clinical
malaria episodes that lead to drug treatment and clearance of
parasites, followed by a continued decrease in MOI as EIR
drops after the rains cease in October. Since vaccination
could reduce MOI, as it has in previous malaria vaccine trials
[35,45,46], it is important to document the reduced frequency
of mixed infections over the course of the transmission
season at this site to allow these natural ﬂuctuations to be
distinguished from the effects of a vaccine.
The associations between MOI, age, and time do not appear
to be confounded by parasite density, though the data suggest
that MOI is higher in infections with moderate parasitemias.
The apparent decrease in MOI in higher-parasitemia in-
fections may reﬂect the rapid growth of a disease-causing
parasite clone overtaking the infection and masking the
presence of minor alleles.
This study also demonstrated a reduced frequency of three
speciﬁc MSP-119 haplotypes in symptomatic infections
compared to asymptomatic infections, including one hap-
lotype (ETSSRL [3D7]) currently being targeted for vaccines
[29]. This association appears to be due to these haplotypes
having a higher prevalence in low parasitemia infections.
Vaccination against haplotypes associated with favorable
clinical outcomes instead of those associated with poor
clinical outcomes could result in increased morbidity and
mortality in the human population. Although analyses of the
within-host dynamics of MSP-119 diversity suggest that a
change in amino acid at speciﬁc residues may be more
important than having any particular haplotype, it will be
important to examine the association between MSP-119
haplotypes and clinical malaria in other endemic regions
and in the context of genome-wide analyses to determine
whether these three haplotypes are inherently less virulent
(or are linked to important virulence factors) or whether
these associations are an artifact of the haplotype dynamics at
this particular site.
Conclusions
This molecular epidemiology study provides information
needed to accurately measure and interpret population
responses to an MSP-1-based malaria vaccine in clinical trials
of vaccine efﬁcacy. It also provides insight into which MSP-
119 polymorphisms may be most relevant to cross-protective
immunity and thus informs vaccine design. If immunity
elicited by such a vaccine is allele speciﬁc, a vaccine derived
from either the FVO or FUP strain might have better initial
efﬁcacy in settings where these MSP-119 haplotypes predom-
inate and haplotypes corresponding to the leading vaccine
strain, 3D7, are less frequent. Given the polymorphic nature
of vaccine antigens for P. falciparum and other genetically
diverse pathogens, it is important to monitor pathogen
populations before, during, and after introduction of
vaccines to determine vaccine efﬁcacy at the molecular level
and to detect potential vaccine-induced changes in the
pathogen population that could compromise vaccine efﬁcacy.
Supporting Information
Accession Numbers
The sequence of msp-1 from the 3D7 strain of P. falciparum was
published with the P. falciparum genome sequence and can be found
under GenBank (http://www.ncbi.nlm.nih.gov/) accession number
XM_001352134.
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Background. Malaria, a tropical parasitic disease, kills about one million
people—mainly children—every year. Most of these deaths are caused
by Plasmodium falciparum, which is transmitted to humans through the
bites of infected mosquitoes. These insects inject a form of the parasite
known as sporozoites into people that replicates inside liver cells without
causing symptoms. Four to five days later, merozoites (another form of
the parasite) are released from the liver cells and invade red blood cells.
Here, they replicate 10-fold before bursting out and infecting other red
blood cells. This massive increase in parasite burden causes malaria’s flu-
like symptoms. If untreated, it also causes anemia (a red blood cell
deficit) and damages the brain and other organs where parasitized red
blood cells sequester. Malaria can be treated with antimalarial drugs and
partly prevented by reducing the chances of being bitten by an infected
mosquito. In addition, researchers are developing vaccines designed to
reduce the global burden of malaria. These contain individual malaria
antigens (proteins from the parasite that stimulate an immune response)
that should, when injected into people, prime the immune system so
that it can rapidly control malaria infections.
Why Was This Study Done? The development of an effective malaria
vaccine is not easy, in part because people can be simultaneously
infected with several parasite strains. These often carry different variants
(alleles) of the genes encoding antigens, which means that the actual
parasite proteins might differ from the ones used for vaccination. If this is
the case, the immune response generated by the vaccine might be less
effective or even ineffective. An ideal vaccine would therefore stimulate
an immune response that recognizes all these strain-specific antigens.
However, little is known about their distribution in parasite populations
in malarial regions, or about how this distribution changes over time (its
dynamics). This information is needed to aid vaccine design and
development. In this study, the researchers have investigated the
distribution and dynamics of genetic variants of a merozoite antigen
called MSP-119, which is included in a vaccine currently being tested in
Mali, West Africa. Although most of the MSP-119 sequence is conserved,
it contains six strain-specific polymorphisms (genetic variations); the
candidate vaccine contains MSP-119 from the 3D7 strain of P. falciparum.
What Did the Researchers Do and Find? The researchers used rapid
DNA sequencing (pyrosequencing) to examine the MSP-119 sequence in
more than 1,300 malaria infections in 100 Malian children. They
compared the frequencies of 14 MSP-119 haplotypes (sets of poly-
morphisms at the six variant sites) over three years, in three age groups,
and in consecutive infections within individuals. They found that the
frequency of individual MSP-119 haplotypes fluctuated in their study
population but that those found in P. falciparum FVO and FUP strains
were always the commonest, each being present in about 40% of the
infections. By contrast, the P. falciparum 3D7 MSP-119 haplotype was
present in only 16% of the infections. They also found that mixed
infections were more common at the start of each malaria season and in
older individuals. In addition, individuals who were infected repeatedly
by parasites from different strains (with different MSP-119 variants)
seemed to get sick with malaria more often than those infected multiple
times by the same strain. The differences might, therefore, be important
in determining the specificity of the immune response to MSP-119.
What Do These Findings Mean? These findings indicate that most
parasites that cause malaria at the Malian test site for the malaria vaccine
that contains 3D7-specific MSP-119 have a different form of MSP-119.
Although early results from field trials suggest that the 3D7-derived
vaccine provides some protection against the more common FVO and
FUP strains, the immunity stimulated by the vaccine might be mainly
allele specific. If this turns out to be the case, these results suggest that a
FVO- or FUP-derived vaccine might be more effective in Mali than the
3D7-derived vaccine, though not necessarily elsewhere. More generally,
these results show the importance of determining the genetics of
pathogen populations before starting vaccine trials. Without this
information, a vaccine’s ability to prevent infections with specific
parasite strains cannot be determined accurately and potentially useful
vaccines might be abandoned if they are tested in inappropriate
populations. Importantly, baseline information of this sort will also allow
vaccine developers to detect any vaccine-induced changes in the
pathogen population that might affect the long-term efficacy of their
vaccines.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040093.
  A related PLoS Medicine Perspective by Colin Sutherland discusses
variation in malaria antigens as a challenge in vaccine development
  The malaria program of the University of Maryland Center for Vaccine
Development performs research on many aspects of malaria
  Information on malaria and the development of vaccines is available
from the Malaria Vaccine Initiative
  The World Health Organization provides links to general information
on malaria plus some specific information on malaria vaccine
development
  MedlinePlus encyclopedia has entries on malaria and on vaccination
  US Centers for Disease Control and Prevention provides information
for patients and professionals on malaria
  US National Institute of Allergy and Infectious Diseases has informa-
tion on malaria, including research into vaccines
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